WO1998058636A1 - Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals - Google Patents

Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals Download PDF

Info

Publication number
WO1998058636A1
WO1998058636A1 PCT/US1998/012231 US9812231W WO9858636A1 WO 1998058636 A1 WO1998058636 A1 WO 1998058636A1 US 9812231 W US9812231 W US 9812231W WO 9858636 A1 WO9858636 A1 WO 9858636A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
attached
independently
nitrogen
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/012231
Other languages
English (en)
French (fr)
Inventor
Daniela Salvemini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Priority to DK98929022T priority Critical patent/DK1001752T3/da
Priority to JP50459399A priority patent/JP2002506445A/ja
Priority to EP98929022A priority patent/EP1001752B1/en
Priority to DE69820633T priority patent/DE69820633T2/de
Priority to AU80685/98A priority patent/AU733415B2/en
Priority to AT98929022T priority patent/ATE256467T1/de
Priority to CA002294155A priority patent/CA2294155A1/en
Publication of WO1998058636A1 publication Critical patent/WO1998058636A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
PCT/US1998/012231 1997-06-20 1998-06-15 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals Ceased WO1998058636A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK98929022T DK1001752T3 (da) 1997-06-20 1998-06-15 Analgetiske fremgangsmåder under anvendelse af syntetiske katalysatorer til dismutation af superoxidradikaler
JP50459399A JP2002506445A (ja) 1997-06-20 1998-06-15 スーパーオキシドラジカルの不均化反応のための合成触媒を用いる鎮痛方法
EP98929022A EP1001752B1 (en) 1997-06-20 1998-06-15 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
DE69820633T DE69820633T2 (de) 1997-06-20 1998-06-15 Analgetische verfahren, die synthetischen katalysatoren zur dismutierung von superoxid radicalen verwenden
AU80685/98A AU733415B2 (en) 1997-06-20 1998-06-15 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
AT98929022T ATE256467T1 (de) 1997-06-20 1998-06-15 Analgetische verfahren, die synthetischen katalysatoren zur dismutierung von superoxid radicalen verwenden
CA002294155A CA2294155A1 (en) 1997-06-20 1998-06-15 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5040297P 1997-06-20 1997-06-20
US60/050,402 1997-06-20

Publications (1)

Publication Number Publication Date
WO1998058636A1 true WO1998058636A1 (en) 1998-12-30

Family

ID=21965044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/012231 Ceased WO1998058636A1 (en) 1997-06-20 1998-06-15 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Country Status (12)

Country Link
US (2) US6180620B1 (enExample)
EP (1) EP1001752B1 (enExample)
JP (1) JP2002506445A (enExample)
AT (1) ATE256467T1 (enExample)
AU (1) AU733415B2 (enExample)
CA (1) CA2294155A1 (enExample)
DE (1) DE69820633T2 (enExample)
DK (1) DK1001752T3 (enExample)
ES (1) ES2215305T3 (enExample)
PT (1) PT1001752E (enExample)
WO (1) WO1998058636A1 (enExample)
ZA (1) ZA985376B (enExample)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
WO2000072893A3 (en) * 1999-05-27 2001-08-30 Monsanto Co Biomaterials modified with superoxide dismutase mimics
WO2003000696A1 (en) * 2001-06-26 2003-01-03 Metaphore Pharmaceuticals, Inc. COMBINATION THERAPY OF AN SODm AND A CORTICOSTEROID FOR PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASE
WO2002058686A3 (en) * 2001-01-26 2003-02-06 Metaphore Pharmaceuticals Inc Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
WO2003024434A3 (en) * 2000-12-08 2004-02-26 Metaphore Pharmaceuticals Inc Use of a superoxide dismutase mimetic catalyst in the manufacture of a medicament for preventing and treating hiv-mediated central nervous system damage
WO2005060974A1 (en) 2003-12-11 2005-07-07 Alcon, Inc. Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
US6916799B2 (en) 1997-11-03 2005-07-12 Duke University Substituted porphyrins
US7470677B2 (en) 1993-10-15 2008-12-30 Aeolus Pharmaceuticals, Inc. Oxidant scavengers
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins
US7754706B2 (en) 2002-12-06 2010-07-13 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
US7759333B2 (en) 2001-12-14 2010-07-20 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
US8217026B2 (en) 1999-01-25 2012-07-10 Aeolus Sciences, Inc. Substituted porphyrins
US8263568B2 (en) * 2001-03-02 2012-09-11 Galera Therapeutics, Llc Chromatography of metal complexes
US8470808B2 (en) 1999-01-25 2013-06-25 Jon D. Piganelli Oxidant scavengers for treatment of type I diabetes or type II diabetes
EP2312309B1 (en) * 2001-03-02 2017-11-01 Galera Labs, LLC Enzyme mimetic metal complexes
US10493081B2 (en) 2011-09-26 2019-12-03 Galera Labs, Llc Methods for treatment of diseases
US10597415B2 (en) 2015-08-11 2020-03-24 Galera Labs, Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
US10610533B2 (en) 2006-10-12 2020-04-07 Galera Labs, Llc Methods of treating oral mucositis
WO2021163397A1 (en) 2020-02-13 2021-08-19 Teva Pharmaceuticals International Gmbh Solid state forms of avasopasem manganese and process for preparation thereof
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
US11382895B2 (en) 2008-05-23 2022-07-12 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
US12156863B2 (en) 2016-09-01 2024-12-03 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
US12220420B2 (en) 2016-05-03 2025-02-11 Galera Labs, Llc Combination therapy for cancer treatment

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270639A1 (en) * 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20050171198A1 (en) * 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US20050175580A1 (en) * 2001-01-05 2005-08-11 Daniela Salvemini Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
ATE439134T1 (de) * 2001-01-19 2009-08-15 Nat Jewish Med & Res Center Medikament zum schutz in der radiotherapie
AU2002315001A1 (en) * 2001-06-08 2002-12-23 Metaphore Pharmaceuticals, Inc. Libraries of conformationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same
WO2003039561A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
US20030232784A1 (en) * 2002-06-14 2003-12-18 Benedict James J. Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
CA2397684A1 (en) * 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
CA2499994C (en) * 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
CN1717234A (zh) * 2002-12-06 2006-01-04 爱尔康公司 用于治疗眼紊乱和疾病的超氧化物岐化酶模拟物
KR100648618B1 (ko) * 2003-11-19 2006-11-23 주식회사 웰스킨 활성 산소 억제제
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
US8217166B2 (en) * 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006069326A2 (en) * 2004-12-21 2006-06-29 Metaphore Pharmaceuticals, Inc. Polyethylene glycolated superoxide dismutase mimetics
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
WO2009065059A2 (en) 2007-11-14 2009-05-22 Kereos, Inc. Super-oxide dismutase mimetics
ES2530462T3 (es) 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
CA3053779A1 (en) 2017-02-15 2018-08-23 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
AU2019215032A1 (en) 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2025024390A2 (en) * 2023-07-21 2025-01-30 Galera Labs, Llc Carcinogenesis reduction with pentaaza macrocyclic ring complex

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63313581A (ja) * 1987-06-16 1988-12-21 Ube Ind Ltd 修飾ス−パ−オキシドジスムタ−ゼ
US4999347A (en) * 1986-08-28 1991-03-12 Sorenson John R J Analgesic method
EP0524161A1 (en) * 1991-07-19 1993-01-20 Monsanto Company Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide
CN1088086A (zh) * 1992-12-14 1994-06-22 西北大学 一种新型的护肤保健品
WO1994015925A1 (en) * 1993-01-14 1994-07-21 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5541174A (en) * 1986-08-28 1996-07-30 Sorenson; John R. J. Analgesic method
WO1996039396A1 (en) * 1995-06-06 1996-12-12 Monsanto Company Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
IL125889A0 (en) 1996-03-13 1999-04-11 Monsanto Co Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999347A (en) * 1986-08-28 1991-03-12 Sorenson John R J Analgesic method
US5541174A (en) * 1986-08-28 1996-07-30 Sorenson; John R. J. Analgesic method
JPS63313581A (ja) * 1987-06-16 1988-12-21 Ube Ind Ltd 修飾ス−パ−オキシドジスムタ−ゼ
EP0524161A1 (en) * 1991-07-19 1993-01-20 Monsanto Company Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide
CN1088086A (zh) * 1992-12-14 1994-06-22 西北大学 一种新型的护肤保健品
WO1994015925A1 (en) * 1993-01-14 1994-07-21 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1996039396A1 (en) * 1995-06-06 1996-12-12 Monsanto Company Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
"DORLAND'S ILLUSTRATED MEDICAL DICTIONARY", 1985, W.B.SAUNDERS COMPANY, XP002081039 *
A. KOHUT ET AL.: "EFFECT OF ALLOPURINOL AND SUPEROXIDE DISMUTASE ON INDOMETHACIN-INDUCED GASTRIC LESIONS IN THE RAT", PHYSIOLOGICAL RESEARCH, vol. 42, 1993, pages 273 - 276, XP002081036 *
B.C. DEL VILLANO ET AL.: "ELEVATED SUPEROXIDE DISMUTASE IN BLACK ALOHOLICS", SCIENCE, vol. 207, no. 4434, 1980, pages 991 - 993, XP002081038 *
CHEMICAL ABSTRACTS, vol. 111, no. 15, 9 October 1989, Columbus, Ohio, US; abstract no. 129816, "MODIFIED SUPEROXIDE DISMUTASE AS INFLAMMATION INHIBITOR AND OTHERS" XP002081040 *
DATABASE WPI Section Ch Week 9531, Derwent World Patents Index; Class B04, AN 95-232188, XP002081041 *
E. LENGFELDER ET AL.: "SUPEROXIDE DISMUTATION BY LOW MOLECULAR WEIGHT CU-COMPLEXES", CLINICAL RESPIRATORY PHYSIOLOGY, vol. 17, 1981, pages 73 - 80, XP002081029 *
ELMER G I ET AL: "TRANSGENIC SUPEROXIDE DISMUTASE MICE DIFFER IN OPIOID-INDUCED ANALGESIA", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 283, no. 1/03, 1995, pages 227 - 232, XP000602399 *
J.L. JOYAVE ET AL.: "ALTERATION OF CHEMICALLY INDUCED HEPATOTOXICITY BY COPPER (II) (3,5-DIISOPROPYLSALICYLATE)2", BIOCHEMICAL PHARMACOLOGY, vol. 34, no. 21, 1985, pages 3915 - 3919, XP002081037 *
M. TAL: "A NOVEL ANTIOXIDANT ALLEVIATES HEAT HYPERALGESIA IN RATS WITH AN EXPERIMENTAL PAINFUL PERIPHERAL NEUROPATHY", NEUROREPORT, vol. 7, no. 8, 1996, pages 1382 - 1384, XP002081031 *
N. GOLDSTEIN ET AL.: "EXOGENOUS GASEOUS SUPEROXIDE POTENTIATES THE ANTINOCICEPTIVE EFFECT OF OPIOID ANALGESIC AGENTS", INFLAMMATION RESEARCH, vol. 45, no. 9, 1996, pages 473 - 478, XP002081033 *
R. VARSANO ET AL.: "SUPEROXIDE DISMUTASE ACTIVITY IN MORPHINE AND MEPERIDINE ADDICTED MICE AND THEIR RESPONSE TO PARAQUAT POISONING", FRESENIUS ENVIR. BULL., vol. 1, 1992, pages S54 - S59, XP002081034 *
RT LI ET AL.: "SYNTHESIS AND PHARMACOLOGICAL ACTIVITIES OF 1,1-DIALKYL-4 (3-BROMOPROPIONYL) PIPERAZINIUM BROMIDES", ACTA PHARMACEUTICA SINICA, vol. 31, no. 10, 1996, pages 757 - 760, XP002081032 *
S. OKUYAMA ET AL.: "COPPER COMPLEXES OF NON-STEROIDAL ANTIINFLAMMATORY AGENTS: ANALGESIC ACTIVITY AND POSSIBLE OPIOID RECEPTOR ACTIVATION", AGENTS AND ACTIONS, vol. 21, no. 1/2, 1987, pages 130 - 144, XP002081028 *
S.T. SHUFF ET AL.: "STABLE SUPEROXIDE DISMUTASE (SOD)-MIMETIC TERNARY HUMAN SERUM ALBUMIN-CU(II)(3,5-DIISOPROPYLSALICYLATE)2/CU(II)2(3,5-DIISOPROPYLSALICYLATE)4 COMPLEXES IN TISSUE DISTRIBUTION OF THE BINARY COMPLEX", BIOCHEMICAL PHARMACOLOGY, vol. 43, no. 7, 1992, pages 1601 - 1612, XP002081030 *
Y.LIN ET AL.: "USE OF SUPEROXIDE DISMUTASE (SOD) IN PATIENTS WITH TEMPOROMANDIBULAR JOINT DYSFUNCTION-A PRELIMINARY STUDY", INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, vol. 23, 1994, pages 428 - 429, XP002081035 *

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470677B2 (en) 1993-10-15 2008-12-30 Aeolus Pharmaceuticals, Inc. Oxidant scavengers
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6916799B2 (en) 1997-11-03 2005-07-12 Duke University Substituted porphyrins
US8546562B2 (en) 1999-01-25 2013-10-01 James D. Crapo Substituted porphyrins
US8946202B2 (en) 1999-01-25 2015-02-03 Aeolus Sciences, Inc. Substituted porphyrins
US8470808B2 (en) 1999-01-25 2013-06-25 Jon D. Piganelli Oxidant scavengers for treatment of type I diabetes or type II diabetes
US8217026B2 (en) 1999-01-25 2012-07-10 Aeolus Sciences, Inc. Substituted porphyrins
US7004976B2 (en) 1999-05-27 2006-02-28 Pharmacia Corporation Biopolymers modified with superoxide dismutase mimics
US7445641B1 (en) 1999-05-27 2008-11-04 Pharmacia Corporation Biomaterials modified with superoxide dismutase mimics
WO2000072893A3 (en) * 1999-05-27 2001-08-30 Monsanto Co Biomaterials modified with superoxide dismutase mimics
JP2003509423A (ja) * 1999-09-16 2003-03-11 フアルマシア・コーポレーシヨン スーパーオキシドジスムターゼ活性を有する置換型ピリジノペンタアザ大環錯体
EP1420019A1 (en) * 1999-09-16 2004-05-19 Monsanto Company Substituted pyridino pentaazamacrocyle ligands having superoxide dismutase activity
EP1420022A1 (en) * 1999-09-16 2004-05-19 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
JP2012097097A (ja) * 1999-09-16 2012-05-24 Pharmacia Corp スーパーオキシドジスムターゼ活性を有する置換型ピリジノペンタアザ大環錯体
WO2003024434A3 (en) * 2000-12-08 2004-02-26 Metaphore Pharmaceuticals Inc Use of a superoxide dismutase mimetic catalyst in the manufacture of a medicament for preventing and treating hiv-mediated central nervous system damage
WO2002058686A3 (en) * 2001-01-26 2003-02-06 Metaphore Pharmaceuticals Inc Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US8263568B2 (en) * 2001-03-02 2012-09-11 Galera Therapeutics, Llc Chromatography of metal complexes
US8444856B2 (en) 2001-03-02 2013-05-21 Galera Therapeutics, Llc Chromatography of metal complexes
EP2312309B1 (en) * 2001-03-02 2017-11-01 Galera Labs, LLC Enzyme mimetic metal complexes
US9222922B2 (en) 2001-03-02 2015-12-29 Galera Labs, Llc Chromatography of metal complexes
US8808545B2 (en) 2001-03-02 2014-08-19 Galera Therapeutics, Llc Chromatography of metal complexes
WO2003000696A1 (en) * 2001-06-26 2003-01-03 Metaphore Pharmaceuticals, Inc. COMBINATION THERAPY OF AN SODm AND A CORTICOSTEROID FOR PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASE
US7759333B2 (en) 2001-12-14 2010-07-20 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
US8003635B2 (en) 2001-12-14 2011-08-23 Novartis Ag Superoxide dismutase mimics for the treatment of ocular disorders and diseases
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins
US7754706B2 (en) 2002-12-06 2010-07-13 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
US8067405B2 (en) 2002-12-06 2011-11-29 Novartis Ag Superoxide dismutase mimics for the treatment of ocular disorders and diseases
WO2005060974A1 (en) 2003-12-11 2005-07-07 Alcon, Inc. Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
US10610533B2 (en) 2006-10-12 2020-04-07 Galera Labs, Llc Methods of treating oral mucositis
US11612608B2 (en) 2006-10-12 2023-03-28 Galera Labs, Llc Methods of treating oral mucositis
US11382895B2 (en) 2008-05-23 2022-07-12 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
US10493081B2 (en) 2011-09-26 2019-12-03 Galera Labs, Llc Methods for treatment of diseases
US11826373B2 (en) 2011-09-26 2023-11-28 Galera Labs, Llc Methods for treatment of diseases
US10597415B2 (en) 2015-08-11 2020-03-24 Galera Labs, Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
US11066433B2 (en) 2015-08-11 2021-07-20 Galera Labs, Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
US12077549B2 (en) 2015-08-11 2024-09-03 Galera Labs, Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
US12220420B2 (en) 2016-05-03 2025-02-11 Galera Labs, Llc Combination therapy for cancer treatment
US12156863B2 (en) 2016-09-01 2024-12-03 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
US20230071463A1 (en) * 2020-02-13 2023-03-09 Teva Pharmaceuticals International Gmbh Solid state forms of avasopasem manganese and process for preparation thereof
WO2021163397A1 (en) 2020-02-13 2021-08-19 Teva Pharmaceuticals International Gmbh Solid state forms of avasopasem manganese and process for preparation thereof

Also Published As

Publication number Publication date
AU733415B2 (en) 2001-05-17
ATE256467T1 (de) 2004-01-15
DK1001752T3 (da) 2004-04-19
DE69820633D1 (de) 2004-01-29
DE69820633T2 (de) 2004-09-23
CA2294155A1 (en) 1998-12-30
AU8068598A (en) 1999-01-04
EP1001752A1 (en) 2000-05-24
EP1001752B1 (en) 2003-12-17
US6395725B1 (en) 2002-05-28
ZA985376B (en) 1999-06-21
ES2215305T3 (es) 2004-10-01
PT1001752E (pt) 2004-05-31
JP2002506445A (ja) 2002-02-26
US6180620B1 (en) 2001-01-30

Similar Documents

Publication Publication Date Title
US6180620B1 (en) Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
Liu et al. Design of clinically useful iron (III)‐selective chelators
Seelig et al. Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats
JP2012097097A (ja) スーパーオキシドジスムターゼ活性を有する置換型ピリジノペンタアザ大環錯体
US20040147498A1 (en) Combinations of superoxide dismutase mimetics and nonsteroidal analgesic / anti-inflammatory drugs
HUE029940T2 (en) Bis (imidazolyl) compounds and radionuclide complexes
AU2011211223B2 (en) Therapeutic or prophylactic agent for biliary diseases
JP3665354B2 (ja) 痛みの治療用及びモルヒネ依存回避用のフルピルチン及びモルヒネからなる組合せ製剤、及びその製法
CA3053779A1 (en) Pentaaza macrocyclic ring complexes for local intestinal delivery
PT1096936E (pt) Tratamento da discinesia
JP5416327B2 (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
EP3560516A1 (en) Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
CA2187794A1 (en) Benzamide-containing pharmaceutical compositions
US20050171198A1 (en) SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
JPS61293910A (ja) 生理学的活性物質のリポソ−ムカプセル化物およびその製造方法
JPH05132430A (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
FR2556216A1 (fr) Nouveau medicament analgesique contenant du proglumide, eventuellement en association avec des medicaments analgesiques-narcotiques
WO2005041886A2 (en) Methods for generating or increasing revenues related to pain inhibitor commerce
HRP20030382A2 (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
WO2000056334A1 (en) Use of imino sugars for anti-tumor therapy
WO2008121322A1 (en) A method of treating neuroblastoma
US20060264408A1 (en) Sod minic multifunctional compounds for treating inflammatory bowel disease
JP2003526659A (ja) 癌の治療のためのカンプトテシンもしくはカンプトテシン誘導体およびアルキル化剤を含んで成る組成物
EP1736155A1 (en) Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
JP2000514047A (ja) 催吐の処置用医薬の製造のためのタキキニンアンタゴニストの使用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 80685/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998929022

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2294155

Country of ref document: CA

Ref country code: CA

Ref document number: 2294155

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998929022

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 80685/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998929022

Country of ref document: EP